Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.
- DOI
- 10.1007/s12032-026-03392-6
- Published
- 2026 Sep 10
- Container
- Medical oncology (Northwood, London, England)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s12032-026-03392-6,
title = {Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.},
author = {Chatterjee S and Arya S and Sharma N and Grover M and Yadav D and Parveen H},
year = {2026},
journal = {Medical oncology (Northwood, London, England)},
doi = {10.1007/s12032-026-03392-6},
url = {https://doi.org/10.1007/s12032-026-03392-6}
}RIS
TY - JOUR TI - Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers. AU - Chatterjee S AU - Arya S AU - Sharma N AU - Grover M AU - Yadav D AU - Parveen H PY - 2026 JO - Medical oncology (Northwood, London, England) DO - 10.1007/s12032-026-03392-6 UR - https://doi.org/10.1007/s12032-026-03392-6 ER -
APA
S, C., S, A., N, S., M, G., D, Y., & H, P. (2026). Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.. Medical oncology (Northwood, London, England). https://doi.org/10.1007/s12032-026-03392-6
Source records
- pubmed · retrieved 2026-09-25T10:35:20.905Z